• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Inhibrx Biosciences Inc (NQ: INBX )

    13.93 +0.59 (+4.42%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 121,010
    Open 13.49
    Bid (Size) 14.10 (5)
    Ask (Size) 14.19 (3)
    Prev. Close 13.34
    Today's Range 13.34 - 14.08
    52wk Range 10.80 - 39.79
    Shares Outstanding 37,892,204
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024
    INBX stock results show that Inhibrx beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024
    INBX stock results show that Inhibrx Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -63.38%
    -63.38%
    1 Month
    -2.59%
    -2.59%
    3 Month
    -59.45%
    -59.45%
    6 Month
    -64.00%
    -64.00%
    1 Year
    -28.01%
    -28.01%

    More News

    Read More
    Top 4 Health Care Stocks That Are Preparing To Pump This Month
    Via Benzinga
    INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
    From Kahn Swick & Foti, LLC
    Via Business Wire
    The NVDA Earnings Effect And What It Means For The Current Market Momentum
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know
    Via Benzinga
    Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients
    Via Benzinga
    Why Is Inhibrx (INBX) Stock Soaring 45% Today?
    Via InvestorPlace
    Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
    Via Talk Markets
    INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx
    Via Investor's Business Daily
    INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
    Via Benzinga
    Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
    Via Benzinga
    $1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying
    Via Benzinga
    Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
    Via Investor's Business Daily
    Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate
    Via Benzinga
    $40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying
    Via Benzinga
    Stocks Reverse Gains After ADP Report
    Via Talk Markets
    Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
    Via Benzinga
    S&P 500 Rises 100 Points; Nasdaq Up 3%
    Via Benzinga
    R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
    Via FinancialNewsMedia
    Topics Death
    Exposures Death
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.